Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
IRONWOOD PHARMACEUTICALS INC
Bear Case (25th pct.)
53.4% vs price
Base Case (Median)
112.1% vs price
Bull Case (75th pct.)
112.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $7.55 | 112.0% | High (40%) |
| EV/EBITDA | $7.55 | 112.0% | Medium (20%) |
| Earnings Power Value | $3.38 | -5.1% | Medium (50%) |
Based on 3 out of 7 methods, IRWD appears undervalued at the current price of $3.56. The base case fair value of $7.55 implies 112.1% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.